BioScrip Inc (NASDAQ:BIOS) Short Interest Update

BioScrip Inc (NASDAQ:BIOS) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 9,810,000 shares, an increase of 19.2% from the August 30th total of 8,230,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently 8.5 days. Approximately 7.5% of the company’s shares are short sold.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in shares of BioScrip during the 2nd quarter valued at about $27,000. Jane Street Group LLC bought a new stake in shares of BioScrip during the 2nd quarter valued at about $30,000. North Star Investment Management Corp. bought a new stake in shares of BioScrip during the 3rd quarter valued at about $64,000. JPMorgan Chase & Co. boosted its stake in shares of BioScrip by 11.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 36,469 shares of the company’s stock valued at $89,000 after purchasing an additional 3,683 shares in the last quarter. Finally, Marathon Capital Management boosted its stake in shares of BioScrip by 9.9% during the 2nd quarter. Marathon Capital Management now owns 47,245 shares of the company’s stock valued at $122,000 after purchasing an additional 4,250 shares in the last quarter. 77.54% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BIOS traded up $0.02 during trading hours on Tuesday, reaching $3.41. 7,735 shares of the company traded hands, compared to its average volume of 1,327,236. The company’s fifty day moving average price is $3.40 and its two-hundred day moving average price is $2.60. The company has a market capitalization of $437.92 million, a price-to-earnings ratio of -6.93 and a beta of 0.45. BioScrip has a 12 month low of $1.56 and a 12 month high of $4.14.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Tuesday, July 30th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04). The firm had revenue of $191.52 million for the quarter, compared to analysts’ expectations of $185.73 million. Equities analysts anticipate that BioScrip will post -0.18 earnings per share for the current fiscal year.

A number of brokerages have issued reports on BIOS. Canaccord Genuity raised their price target on shares of BioScrip from $3.50 to $4.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. BidaskClub lowered shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Thursday, June 20th. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, SunTrust Banks raised their price target on shares of BioScrip from $3.25 to $4.25 and gave the stock a “buy” rating in a report on Friday, September 20th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $4.63.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Featured Story: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.